CTA CTA Pharmacovigilance & Drug Safety 2 — Questions and Answers
Question 1: What is the purpose of a Risk Management Plan (RMP) in pharmacovigilance?
- To outline the financial risks of a clinical trial
- To describe safety concerns of a medicine and how identified risks will be characterized, minimized, and communicated (Correct answer)
- To plan the randomization sequence for a trial
- To document the statistical analysis methodology
Correct answer: To describe safety concerns of a medicine and how identified risks will be characterized, minimized, and communicated
An RMP is a regulatory document that describes a medicine's known and potential safety concerns and outlines the measures planned to minimize and monitor those risks.
Question 2: What is a Periodic Benefit-Risk Evaluation Report (PBRER)?
- A monthly report filed with the IRB about enrollment progress
- A periodic regulatory submission that evaluates the benefit-risk profile of an authorized medicinal product (Correct answer)
- A report submitted at the end of each study phase to the sponsor
- A document listing all protocol amendments during a trial
Correct answer: A periodic regulatory submission that evaluates the benefit-risk profile of an authorized medicinal product
A PBRER is a periodic pharmacovigilance report submitted to regulatory authorities that evaluates the benefit-risk balance of an approved product based on all accumulated safety data.
Question 3: What is the Medical Dictionary for Regulatory Activities (MedDRA)?
- A database of approved drug doses and dosing schedules
- A standardized international medical terminology used to code adverse events and medical conditions in clinical trials (Correct answer)
- A regulatory submission format for new drug applications
- A clinical trial management software platform
Correct answer: A standardized international medical terminology used to code adverse events and medical conditions in clinical trials
MedDRA is a globally harmonized, standardized medical terminology used by regulatory authorities and the pharmaceutical industry to code clinical data, including adverse events, in a consistent manner.
Question 4: In signal detection for pharmacovigilance, what is a 'signal'?
- A confirmed causal relationship between a drug and an adverse event
- Information from one or more sources suggesting a new or changed association between a medicine and an adverse event (Correct answer)
- An automatic alert from a clinical trial management system
- A notification from the FDA about a label update
Correct answer: Information from one or more sources suggesting a new or changed association between a medicine and an adverse event
A pharmacovigilance signal is information suggesting a new or changed association between a medicine and an adverse event that warrants further investigation, but does not necessarily confirm causality.
Question 5: What is the primary function of a global safety database in pharmacovigilance?
- To store financial data about drug development costs
- To collect, manage, and report all individual case safety reports (ICSRs) for a product (Correct answer)
- To track clinical trial enrollment milestones
- To archive regulatory correspondence with health authorities
Correct answer: To collect, manage, and report all individual case safety reports (ICSRs) for a product
A global safety database centralizes all individual case safety reports received for a product, enabling aggregate analysis, signal detection, and regulatory reporting.
Question 6: What is a Dear Healthcare Provider (DHCP) letter used for in drug safety?
- To invite physicians to participate in clinical trials
- To communicate important new safety information about a marketed product to prescribers (Correct answer)
- To notify hospitals of a drug shortage
- To announce FDA approval of a new indication
Correct answer: To communicate important new safety information about a marketed product to prescribers
A DHCP letter (also called a Dear Doctor letter) is a risk communication tool used to rapidly disseminate important safety information about a marketed drug to prescribers and other healthcare professionals.
CTA CTA Pharmacovigilance & Drug Safety 2
What is the purpose of a Risk Management Plan (RMP) in pharmacovigilance?